Relationship Between Optical Coherence Tomography-Derived In-Stent Neoatherosclerosis and the Extent of Lipid-Rich Neointima by Near-Infrared Spectroscopy and Intravascular Ultrasound: A Multimodal Imaging Study.

in‐stent restenosis near‐infrared spectroscopy neoatherosclerosis optical coherence tomography optical frequency domain imaging

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
06 12 2022
Historique:
pubmed: 30 11 2022
medline: 15 12 2022
entrez: 29 11 2022
Statut: ppublish

Résumé

Background In-stent restenosis, especially for neoatherosclerosis, is a major concern following percutaneous coronary intervention. This study aimed to elucidate the association of features of in-stent restenosis lesions revealed by optical coherence tomography (OCT)/optical frequency domain imaging (OFDI) and the extent of lipid-rich neointima (LRN) assessed by near-infrared spectroscopy (NIRS) and intravascular ultrasound, especially for neoatherosclerosis. Methods and Results We analyzed patients undergoing percutaneous coronary intervention for in-stent restenosis lesions using both OCT/OFDI and NIRS-intravascular ultrasound. OCT/OFDI-derived neoatherosclerosis was defined as lipid neointima. The existence of large LRN (defined as a long segment with 4-mm maximum lipid core burden index ≥400) was evaluated by NIRS. In 59 patients with 64 lesions, neoatherosclerosis and large LRN were observed in 17 (26.6%) and 21 lesions (32.8%), respectively. Naturally, large LRN showed higher 4-mm maximum lipid core burden index (median [interquartile range], 623 [518-805] versus 176 [0-524];

Identifiants

pubmed: 36444847
doi: 10.1161/JAHA.122.026569
pmc: PMC9851451
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026569

Références

Eur Heart J Cardiovasc Imaging. 2017 Jun 01;18(6):663-669
pubmed: 27679596
Heart Vessels. 2020 Sep;35(9):1193-1200
pubmed: 32253529
J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72
pubmed: 22421299
Lancet. 2019 Nov 2;394(10209):1629-1637
pubmed: 31570255
J Am Coll Cardiol. 2001 Apr;37(5):1478-92
pubmed: 11300468
Circ Cardiovasc Interv. 2013 Oct 1;6(5):507-17
pubmed: 24065447
J Am Coll Cardiol. 2015 Aug 4;66(5):495-507
pubmed: 26227186
Am Heart J. 2009 Aug;158(2):284-93
pubmed: 19619707
J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6
pubmed: 15172426
JACC Cardiovasc Imaging. 2009 Jul;2(7):858-68
pubmed: 19608137
Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):217-228
pubmed: 33637979
J Am Coll Cardiol. 2011 Mar 15;57(11):1314-22
pubmed: 21376502
Eur Heart J Cardiovasc Imaging. 2021 Jun 22;22(7):824-834
pubmed: 31990323
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
JACC Cardiovasc Interv. 2009 Nov;2(11):1035-46
pubmed: 19926041
Cardiovasc Interv Ther. 2020 Jan;35(1):1-12
pubmed: 31571149
Heart. 2014 Jan;100(2):153-9
pubmed: 24270744
Atherosclerosis. 2015 Oct;242(2):553-9
pubmed: 26318104
Circ Cardiovasc Interv. 2009 Jun;2(3):205-12
pubmed: 20031717
JACC Cardiovasc Imaging. 2008 Sep;1(5):638-48
pubmed: 19356494
JACC Cardiovasc Interv. 2013 Aug;6(8):838-46
pubmed: 23871513
Lancet. 2021 Mar 13;397(10278):985-995
pubmed: 33714389
Int J Cardiol Heart Vasc. 2021 Mar 11;33:100747
pubmed: 33748401
Circulation. 2002 Oct 22;106(17):2200-6
pubmed: 12390948
Circ Cardiovasc Imaging. 2016 Jan;9(1):
pubmed: 26729855
EuroIntervention. 2021 Aug 27;17(6):489-496
pubmed: 32985411
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2511-2523
pubmed: 27889345
Circulation. 2002 Sep 24;106(13):1640-5
pubmed: 12270856
Cardiovasc Interv Ther. 2020 Apr;35(2):105-116
pubmed: 32125622
EuroIntervention. 2016 Dec 10;12(11):e1366-e1374
pubmed: 26690315
Cardiovasc Interv Ther. 2020 Jan;35(1):13-18
pubmed: 31602597
J Cardiol. 2018 Mar;71(3):244-250
pubmed: 29066157
Circulation. 2014 Jan 14;129(2):211-23
pubmed: 24163064
Eur Heart J. 2015 Aug 21;36(32):2147-59
pubmed: 25994755

Auteurs

Mitsuhiro Takeuchi (M)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Tomotaka Dohi (T)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Mitsuaki Matsumura (M)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.
Clinical Trials Center Cardiovascular Research Foundation New York NY.

Tatsuya Fukase (T)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Ryota Nishio (R)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Norihito Takahashi (N)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Hirohisa Endo (H)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Hiroki Nishiyama (H)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Shinichiro Doi (S)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Iwao Okai (I)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Hiroshi Iwata (H)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Shinya Okazaki (S)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Katsumi Miyauchi (K)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Hiroyuki Daida (H)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.

Tohru Minamino (T)

Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.
Japan Agency for Medical Research and Development Core Research for Evolutionary Medical Science and Technology (AMED-CREST) Japan Agency for Medical Research and Development Tokyo Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH